XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue:    
Total revenue $ 2,739 $ 25,364
Operating costs and expenses:    
Cost of goods sold $ 252 $ 21,343
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 9,175 $ 36,489
Selling, general and administrative 8,106 16,714
Restructuring charge 126 0
Total operating costs and expenses 17,659 74,546
Loss from operations (14,920) (49,182)
Interest and other, net    
Interest expense (2,257) (2,092)
Interest income and other income (expenses), net 413 2,235
Total interest and other, net (1,844) 143
Loss from continuing operations before income taxes (16,764) (49,039)
Provision for income taxes 2 7
Loss from continuing operations (16,766) (49,046)
Income from discontinued operations, net of tax 21,405 16,113
Net income (loss) $ 4,639 $ (32,933)
Loss from continuing operations per share - basic $ (0.16) $ (0.49)
Loss from continuing operations per share - diluted (0.16) (0.49)
Income from discontinued operations per share - basic 0.21 0.16
Income from discontinued operations per share - diluted 0.21 0.16
Net income (loss) per share - basic 0.05 (0.33)
Net income (loss) per share - diluted $ 0.05 $ (0.33)
Weighted average number of common shares used to calculate net income (loss) per share:    
Basic 100,954 98,982
Diluted 100,954 98,982
Development and Other Revenue [Member]    
Revenue:    
Total revenue $ 144 $ 878
Drug Product Revenue, Net [Member]    
Revenue:    
Total revenue $ 2,595 $ 24,486